Valion Bio (TIVC) Change in Accured Expenses (2021 - 2025)
Valion Bio has reported Change in Accured Expenses over the past 5 years, most recently at $209000.0 for Q4 2025.
- For Q4 2025, Change in Accured Expenses rose 361.25% year-over-year to $209000.0; the TTM value through Dec 2025 reached $235000.0, up 167.53%, while the annual FY2025 figure was $235000.0, 167.53% up from the prior year.
- Change in Accured Expenses for Q4 2025 was $209000.0 at Valion Bio, up from -$327000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $287000.0 in Q4 2023 and troughed at -$327000.0 in Q3 2025.
- A 5-year average of $11350.0 and a median of -$1500.0 in 2021 define the central range for Change in Accured Expenses.
- Biggest five-year swings in Change in Accured Expenses: surged 394.87% in 2022 and later tumbled 1430.0% in 2023.
- Year by year, Change in Accured Expenses stood at -$39000.0 in 2021, then surged by 394.87% to $115000.0 in 2022, then surged by 149.57% to $287000.0 in 2023, then crashed by 127.87% to -$80000.0 in 2024, then skyrocketed by 361.25% to $209000.0 in 2025.
- Business Quant data shows Change in Accured Expenses for TIVC at $209000.0 in Q4 2025, -$327000.0 in Q3 2025, and $197000.0 in Q2 2025.